Julie Van Coillie

Julie Van Coillie

Auto-generated profile, based on publicly available information

Julie Van Coillie

Department of Experimental Immunohematology Sanquin Research Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
WTWeihua Tian
Weihua Tian
ZYZilu Ye
Zilu Ye
SWShengjun Wang
Shengjun Wang
MSMorten Alder Schulz
Morten Alder Schulz
JCJulie Van Coillie
Julie Van Coillie
ZYZhang Yang
Zhang Yang
Lysosomal replacement enzymes are essential therapeutic options for rare congenital lysosomal enzyme deficiencies, but enzymes in clinical use are only partially effective due to short circulatory half-life and inefficient biodistribution. Replacement enzymes are primarily taken up by cell surface glycan receptors, and glycan structures influence uptake, biodistribution, and circulation time. It has not been possible to design and systematically study effects of different glycan features. Here we present a comprehensive gene engineering screen in Chinese hamster ovary cells that enables production of lysosomal enzymes with N-glycans custom designed to affect key glycan features guiding cellular uptake and circulation. We demonstrate distinct circulation time and organ distribution of selected glycoforms of α-galactosidase A in a Fabry disease mouse model, and find that an α2-3 sialylated glycoform designed to eliminate uptake by the mannose 6-phosphate and mannose receptors exhibits improved circulation time and targeting to hard-to-reach organs such as heart. The developed design matrix and engineered CHO cell lines enables systematic studies towards improving enzyme replacement therapeutics.

16 December 2022 in EBioMedicine
Verified
Journal Article
Open access
JCJulie Van Coillie
Julie Van Coillie
TPTamas Pongracz
Tamas Pongracz
JRJohann Rahmöller
Johann Rahmöller
HCHung-Jen Chen
Hung-Jen Chen
CGChiara Elisabeth Geyer
Chiara Elisabeth Geyer
JWJoost W. Wiersinga
Joost W. Wiersinga
Afucosylated IgG1 responses have only been found against membrane-embedded epitopes, including anti-S in SARS-CoV-2 infections. These responses, intrinsically protective through enhanced FcγRIIIa binding, can also trigger exacerbated pro-inflammatory responses in severe COVID-19. We investigated if the BNT162b2 SARS-CoV-2 mRNA also induced afucosylated IgG responses. Blood from vaccinees during the first vaccination wave was collected. Liquid chromatography-Mass spectrometry (LC-MS) was used to study anti-S IgG1 Fc glycoprofiles. Responsiveness of alveolar-like macrophages to produce proinflammatory cytokines in presence of sera and antigen was tested. Antigen-specific B cells were characterized and glycosyltransferase levels were investigated by Fluorescence-Activated Cell Sorting (FACS). Initial transient afucosylated anti-S IgG1 responses were found in naive vaccinees, but not in antigen-experienced ones. All vaccinees had increased galactosylated and sialylated anti-S IgG1. Both naive and antigen-experienced vaccinees showed relatively low macrophage activation potential, as expected, due to the low antibody levels for naive individuals with afucosylated IgG1, and low afucosylation levels for antigen-experienced individuals with high levels of anti-S. Afucosylation levels correlated with FUT8 expression in antigen-specific plasma cells in naive individuals. Interestingly, low fucosylation of anti-S IgG1 upon seroconversion correlated with high anti-S IgG levels after the second dose. Here, we show that BNT162b2 mRNA vaccination induces transient afucosylated anti-S IgG1 responses in naive individuals. This observation warrants further studies to elucidate the clinical context in which potent afucosylated responses would be preferred. LSBR1721, 1908; 10.13039/501100001826 ZonMW 10430012010021, 09150161910033, 10430012010008; DFG398859914, 400912066, 390884018; PMI; DOI4-Nr. 3; H2020-MSCA-ITN 721815.

8 August 2020 in Glycobiology
Verified
Journal Article
Open access
PDF file
VTVirginia Tajadura-Ortega
Virginia Tajadura-Ortega
GGGennaro Gambardella
Gennaro Gambardella
ASAlexandra Skinner
Alexandra Skinner
AHAdnan Halim
Adnan Halim
JCJulie Van Coillie
Julie Van Coillie
JBJoy Burchell
Joy Burchell
Aberrant mucin-type O-linked glycosylation is a common occurrence in cancer where the upregulation of sialyltransferases is often seen leading to the early termination of O-glycan chains. Mucin-type O-linked glycosylation is not limited to mucins and occurs on many cell surface glycoproteins including EGFR, where the number of sites can be limited. Upon EGF ligation, EGFR induces a signaling cascade and may also translocate to the nucleus where it directly regulates gene transcription, a process modulated by Galectin-3 and MUC1 in some cancers. Here, we show that upon EGF binding, breast cancer cells carrying different O-glycans respond by transcribing different gene expression signatures. MMP10, the principal gene upregulated when cells carrying sialylated core 1 glycans were stimulated with EGF, is also upregulated in ER-positive breast carcinoma reported to express high levels of ST3Gal1 and hence mainly core 1 sialylated O-glycans. In contrast, isogenic cells engineered to carry core 2 glycans upregulate CX3CL1 and FGFBP1 and these genes are upregulated in ER-negative breast carcinomas, also known to express longer core 2 O-glycans. Changes in O-glycosylation did not significantly alter signal transduction downstream of EGFR in core 1 or core 2 O-glycan expressing cells. However, striking changes were observed in the formation of an EGFR/galectin-3/MUC1/β-catenin complex at the cell surface that is present in cells carrying short core 1-based O-glycans but absent in core 2 carrying cells.

14 August 2023 in iScience
Verified
Journal Article
Open access
JCJulie Van Coillie
Julie Van Coillie
TPTamas Pongracz
Tamas Pongracz
TŠTonći Šuštić
Tonći Šuštić
WWWenjun Wang
Wenjun Wang
JNJan Nouta
Jan Nouta
MEMeral Esen
Meral Esen
IgG antibodies are important mediators of vaccine-induced immunity through complement- and Fc receptor-dependent effector functions. Both are influenced by the composition of the conserved N-linked glycan located in the IgG Fc domain. Here, we compared the anti-Spike (S) IgG1 Fc glycosylation profiles in response to mRNA, adenoviral, and protein-based COVID-19 vaccines by mass spectrometry (MS). All vaccines induced a transient increase of antigen-specific IgG1 Fc galactosylation and sialylation. An initial, transient increase of afucosylated IgG was induced by membrane-encoding S protein formulations. A fucose-sensitive ELISA for antigen-specific IgG (FEASI) exploiting FcγRIIIa affinity for afucosylated IgG was used as an orthogonal method to confirm the LC-MS-based afucosylation readout. Our data suggest that vaccine-induced anti-S IgG glycosylation is dynamic, and although variation is seen between different vaccine platforms and individuals, the evolution of glycosylation patterns display marked overlaps.

11 August 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
JCJulie Van Coillie
Julie Van Coillie
TPTamas Pongracz
Tamas Pongracz
JRJohann Rahmöller
Johann Rahmöller
HCHung-Jen Chen
Hung-Jen Chen
CGChiara E. Geyer
Chiara E. Geyer
AGAmsterdam UMC COVID-19 S3/HCW Study Group
Amsterdam UMC COVID-19 S3/HCW Study Group
Background: Afucosylated IgG responses have been found only against membrane-embedded epitopes, including anti-S in SARS-CoV-2 infections. These responses, intrinsically protective through enhanced FcgRIIIa binding, also trigger exacerbated pro-inflammatory responses in severe COVID-19. We investigated if the BNT162b2 SARS-CoV-2 mRNA also induced afucosylated IgG responses. Methods: Blood from vaccinees during the first vaccination wave was collected. MS was used to study anti-S IgG1-Fc glycoprofiling. Responsiveness of alveolar-like macrophages to produce proinflammatory cytokines in presence of sera and antigen was tested. Antigen-specific B cells were characterized and glycosyltransferase levels were investigated by FACS. Findings: Transient afucosylated anti-S IgG1 responses were found in naive vaccinees, but not in antigen-experienced vaccinees. All vaccinees had increased galactosylation and sialylation of anti-S IgG1. Both naive and antigen-experienced vaccinees showed relative low macrophage activation potential as expected due to the low antibody levels for naive individuals with afucosylated IgG, and high fucosylation levels for antigen-experienced individuals with high levels of anti-S. Afucosylation levels correlated with FUT8 expression in antigen-specific plasma cells in naive individuals. Importantly, low fucosylation of anti-S IgG upon seroconversion correlated with high IgG levels after the second dose. Interpretation: Here, for the first time, we show that BNT162b2 mRNA vaccination induces transient afucosylated anti-S IgG1 responses in naive individuals. This observation warrants further studies to elucidate the clinical context in which potent afucosylated responses would be preferred. Funding: LSBR 1721, 1908; ZonMW 10430012010021, 09150161910033; DFG 398859914, 400912066, 390884018; PMI; DOI4-Nr. 3; H2020-MSCA-ITN 721815. Declaration of Interest: The authors declare that they have no conflicts of interest. Ethical Approval: The ethics committee of the AUMC approved the study.

15 February 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJulie Van Coillie
Julie Van Coillie
TPTamas Pongracz
Tamas Pongracz
JRJohann Rahmöller
Johann Rahmöller
HCHung-Jen Chen
Hung-Jen Chen
CGChiara Geyer
Chiara Geyer
UGUMC COVID-19 S3/HCW study group
UMC COVID-19 S3/HCW study group
The onset of severe SARS-CoV-2 infection is characterized by the presence of afucosylated IgG1 responses against the viral spike (S) protein, which can trigger exacerbated inflammatory responses. Here, we studied IgG glycosylation after BNT162b2 SARS-CoV-2 mRNA vaccination to explore whether vaccine-induced S protein expression on host cells also generates afucosylated IgG1 responses. SARS-CoV-2 naive individuals initially showed a transient afucosylated anti-S IgG1 response after the first dose, albeit to a lower extent than severely ill COVID-19 patients. In contrast, previously infected, antigen-experienced individuals had low afucosylation levels, which slightly increased after immunization. Afucosylation levels after the first dose correlated with low fucosyltransferase 8 (FUT8) expression levels in a defined plasma cell subset. Remarkably, IgG afucosylation levels after primary vaccination correlated significantly with IgG levels after the second dose. Further studies are needed to assess efficacy, inflammatory potential, and protective capacity of afucosylated IgG responses. One sentence summary A transient afucosylated IgG response to the BNT162b2 mRNA vaccine was observed in naive but not in antigen-experienced individuals, which predicted antibody titers upon the second dose.